Division of Hematology, Department of Internal Medicine, Hacettepe University, 06800 Ankara, Turkey.
Medicina (Kaunas). 2022 Nov 1;58(11):1575. doi: 10.3390/medicina58111575.
The SARS-CoV-2 spike protein mRNA-based vaccines have prevented countless mortality and morbidity, and have an excellent risk/benefit ratio. However, various adverse events may rarely occur after the BNT162b2 vaccine, like any other medical intervention. The COVID-19 itself and the spike protein produced endogenously by mRNA vaccines may have immunological, microenvironmental, prothrombotic, and neoplastic effects. As a contribution to the published report, we would like to share our experience regarding four cases in which myeloid neoplasms emerged following the vaccination. : There is no doubt that vaccination could continue along the lines of established universal recommendations. Meanwhile, all hematological adverse events must be closely monitored and reported. Further efforts should be focused on the probable pathobiological mechanisms and causalities of spike protein-related toxicity and clonal myeloid disorders.
基于 SARS-CoV-2 刺突蛋白的 mRNA 疫苗已经预防了无数的死亡和发病，并且具有极好的风险/收益比。然而，与任何其他医疗干预一样，BNT162b2 疫苗接种后也可能会很少出现各种不良反应。COVID-19 本身和 mRNA 疫苗内源性产生的刺突蛋白可能具有免疫、微环境、促血栓形成和肿瘤形成的作用。作为对已发表报告的贡献，我们想分享我们在接种疫苗后出现 4 例髓系肿瘤的经验。毫无疑问，疫苗接种可以继续按照既定的普遍建议进行。同时，必须密切监测和报告所有血液学不良反应。应进一步努力关注与刺突蛋白相关毒性和克隆性髓系疾病的可能病理生物学机制和因果关系。
